Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Annals Of Nutrition And Metabolism Publishes New Recommendations On Fat Consumption By 40 Of The World's Leaders In Diet Nutrition And Health
Reports published today in the Annals of Nutrition and Metabolism suggest that many people are confused about the health consequences of fats consumed. Often fat is not considered to be part of a healthy, balanced diet. Also many do not know that there are good, and even essential, fats. As a result, the quality of fats they consume is not in line with recommendations. To help overcome this problem, experts suggest that simple dietary changes be made, such as replacing full fat dairy (e.g. fatty cheeses) and meat products with lean choices, and use of fats and oils of vegetable origin rich in essential fats (sunflower oil, rapeseed oil, soybean oil and products made of these oils such as margarines) rather than of consuming fat of animal origin (lard, butter, etc).
generic viagra online
As Flu Pandemic Declared, Leaders Must Focus On Poor Countries To Avert 'Bleaker Picture'
As the World Health Organization raised the pandemic alert for Influenza A (H1N1) to its highest level, humanitarian specialists are calling on governments and health authorities globally to strengthen poor communities" access to primary health care and protect the most at risk.
News of the day
Overwhelming Medicare Plan Choices Spell Confusion
In a sign of the challenges facing seniors on Medicare, a new study finds that older Americans are more likely to make poor choices when faced with a wide array of drug-coverage plans. Making matters worse, many are confident they made the right decisions.
Endocrinology

HELP Committee Approves Protection For High Tech Drug Companies From Generics

"Senators agreed Monday to give high-tech biologic drugs 12 years of market protection before generic versions can compete," according to The Associated Press. The AP reports: "The vote in the Senate Health, Education, Labor and Pensions Committee was a victory for the biotechnology and pharmaceutical industries but a defeat for the Obama administration and AARP. The Obama administration had pushed for a seven-year exclusivity period so that patients could get quicker access to cheaper versions of costly medicines used to treat ailments including cancer, Parkinson"s, diabetes and rheumatoid arthritis. Proponents of the longer time frame say products like the blockbuster cancer drug Avastin deserve longer market protection because they are more expensive and time-consuming to produce than regular drugs, and the extra time and money is needed to attract investors and promote innovation. ... The decision would still need agreement from the full Senate and the House, where Energy and Commerce Committee Chairman Henry Waxman, D-Calif., strongly supporters a shorter exclusivity period." The AP notes: "Biotech drugs currently don"t face generic competition because the Food and Drug Administration doesn"t have power to approve copies of such medications. Efforts to change that have been held up for nearly a decade by squabbling between the biotech and generic drug industries and their allies on Capitol Hill" (Werner, 7/14). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009